EXETER, N.H.--(BUSINESS WIRE)--CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today announced the publication of study results of a clinical trial with the Company’s proprietary investigational intranasal insulin candidate, Nasulin™ in the November 2008 issue of the Journal of Diabetes Science and Technology. In a peer-reviewed article entitled “Pharmacokinetics and Pharmacodynamics of Intranasal Insulin Spray (Nasulin™) Administered to Healthy Male Volunteers: Influence of the Nasal Cycle,” the authors report that the intranasal insulin formulation was generally well tolerated, well absorbed and the drug can be administered without regard to the nasal cycle. The study was conducted by investigators from the National University of Ireland, Cork & Shandon Clinic and CPEX Pharmaceuticals.
